Neoadjuvant Radiotherapy Versus Surgery Alone for Stage II/III Mid-low Rectal Cancer With or Without High-risk Factors

医学 全直肠系膜切除术 累积发病率 放射治疗 结直肠癌 临床终点 外科 入射(几何) 阶段(地层学) 内科学 随机对照试验 癌症 队列 生物 光学 物理 古生物学
作者
Xiangbing Deng,Ping Liu,Dan Jiang,Mingtian Wei,Xin Wang,Xuyang Yang,Yuanchuan Zhang,Bing Wu,Yanjun Liu,Meng Qiu,Hua Zhuang,Zong‐Guang Zhou,Yunfeng Li,Feng Xu,Ziqiang Wang
出处
期刊:Annals of Surgery [Lippincott Williams & Wilkins]
卷期号:272 (6): 1060-1069 被引量:53
标识
DOI:10.1097/sla.0000000000003649
摘要

OBJECTIVE: The aim of this study was to compare stage II/III rectal cancers with or without high-risk factors, and evaluate the effect of neoadjuvant radiotherapy (NRT) in these 2 cohorts. BACKGROUND: NRT is often used in stage II/III rectal cancers to improve local control, while not affecting overall survival. However, good-quality surgery without NRT may also achieve good local control in selected patients. METHODS: According to risk-stratification criteria and clinical staging, consecutive eligible participants of stage II/III rectal cancer were preoperatively classified into patients with (high-risk) or without (low-risk) high-risk factors. Both groups were respectively randomized to receive either short-course radiotherapy (SCRT) + total mesorectal excision (TME) or TME alone, forming the following 4 groups: high-risk patients with (HiR) or without (HiS) radiation, and low-risk patients with (LoR) or without (LoS) radiation. The primary endpoint was local recurrence. The secondary endpoints included overall survival, disease-free survival, distant recurrence, quality of surgery, and safety (NCT01437514). RESULTS: In total, 401 patients were analyzed. With a median 54 months' follow-up, low-risk patients obtained better 3-year cumulative incidence of local recurrence (2.2% vs 11.0%, P = 0.006), overall survival rate (86.9%vs 76.5%, P = 0.002), disease-free survival rate (87.0% vs 67.9%, P < 0.001), and cumulative incidence of distant recurrence (12.5% vs 29.4%, P < 0.001) than high-risk patients. With regard to 3-year cumulative incidence of local recurrence, no differences were observed between the LoR and LoS groups (1.2% vs 3.0%, P = 0.983) or the HiR and HiS groups (12.9% vs 8.9%, P = 0.483). CONCLUSIONS AND RELEVANCE: Stratification of stage II/III rectal cancers according to risk factors to more precise subclassifications may result in noteworthy differences in survivals and local pelvic control. An extremely low cumulative incidence of local recurrence and survivals in low-risk patients can be achieved with upfront good quality of surgery alone. This trial, owing to the insufficient power, could not prove the noninferiority of surgery alone, but suggest a discriminative use of NRT according to clinical risk stratification in stage II/III rectal cancer.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
所所应助不呐呐采纳,获得10
刚刚
刚刚
1秒前
1秒前
科研通AI6.2应助淡定秋白采纳,获得20
1秒前
海潮飞翔发布了新的文献求助10
2秒前
2秒前
HanGuilin发布了新的文献求助10
2秒前
怡然的怜烟应助有趣的桃采纳,获得10
3秒前
3秒前
ld543664发布了新的文献求助10
3秒前
超级的访天完成签到,获得积分10
4秒前
转树发布了新的文献求助10
4秒前
yyy发布了新的文献求助10
4秒前
追寻绮玉完成签到,获得积分10
5秒前
丘比特应助小橘子采纳,获得10
5秒前
6秒前
陈红安完成签到,获得积分10
6秒前
6秒前
7秒前
哇咔咔完成签到,获得积分10
7秒前
7秒前
8秒前
Au_应助初景采纳,获得10
8秒前
Seven完成签到,获得积分20
9秒前
孤独千愁完成签到,获得积分10
9秒前
ld543664完成签到,获得积分10
10秒前
11秒前
11秒前
11秒前
胖圈儿发布了新的文献求助10
12秒前
12秒前
小吴应助文件撤销了驳回
12秒前
Au_应助大魁采纳,获得10
12秒前
13秒前
砼砼完成签到,获得积分10
13秒前
XHL发布了新的文献求助10
13秒前
13秒前
高分求助中
Principles of Economics, 11th Edition 10000
University Physics with Modern Physics, 16th edition 10000
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Environmental Leverage in Times of Climate Crisis: Product Standards, Carbon Border Measures and Preferential Trade Agreements 1000
Matrix Methods in Data Mining and Pattern Recognition 510
Social Skills Improvement System-Rating Scales--Chinese Version 500
Dynamische Polarisation von H-1 und B-11 in (CH-3)-3NBH-3 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7243731
求助须知:如何正确求助?哪些是违规求助? 8867931
关于积分的说明 18706344
捐赠科研通 6918292
什么是DOI,文献DOI怎么找? 3196713
关于科研通互助平台的介绍 2370441
邀请新用户注册赠送积分活动 2171347